Summary by Futu AI
On September 3, 2024, WuXi Biologics submitted the disclosure report for the next day, disclosing the changes in its issued shares or treasury shares. According to the Listing Rules of The Stock Exchange of Hong Kong Limited, the company confirms that all share issuances or treasury share sales or transfers have been authorized by the board of directors and comply with relevant laws and regulations. The report shows that on September 3, 2024, WuXi Biologics repurchased 5,430,000 ordinary shares at a repurchase price ranging from HKD 10.88 to HKD 11.28, with a total expenditure of approximately HKD 59,871,690. these shares will be proposed for cancellation and there will be no change in treasury shares. In addition, the company obtained a repurchase authorization on June 19, 2024, and from that date until September 3, 2024, a total of 10,910,000 shares were repurchased, accounting for 0.2628% of the issued shares on that day. After the repurchase, the company will comply with relevant regulations and will not conduct any new share issuances or further sales or transfers of treasury shares until October 3, 2024.